conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data oct
rate updat oct
currenc amount express
methodolog valu compani
gilead perform third quarter larg line
expect product sale hcv
hiv
manag also rais revenu guidanc year
billion account weaker-than-
expect gener hiv competit europ delay
gener pah drug letairi gilead new
guidanc fit well prior billion forecast
although new forecast billion slightli
ahead guidanc given recent posit data
multipl
improv car-t
therapi yescarta upcom nash data first half
maintain per share fair valu
estim share look under-valued think investor
underestim stabil result lower
hcv sale annual expect investor could
comfort firm announc new ceo expect
later year continu think gilead establish
hiv portfolio newer drug oncolog immunolog
dive deeper nash optimist upcom
phase data selonsertib advanc fibrosi
cirrhosi patient particularli interest
combin data atla studi track
becom avail end detail
nash market analysi pleas see recent healthcar
lack credit wide-moat gilead no-moat intercept
hiv strength counter hcv weak although
saw encourag sign busi gilead
hiv busi perform strongli new
combin pill biktarvi drove growth hiv
revenu volum growth global hiv growth
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
develop market therapi treat life-threaten
infecti diseas core portfolio focus hiv
hepat acquisit coru pharma myogen cv
therapeut arresto bioscienc calistoga broaden focu
includ pulmonari cardiovascular diseas cancer gilead
acquisit pharmasset brought right hepat drug sovaldi
also part combin drug harvoni kite acquisit boost
gilead exposur cell therapi oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
weigh declin europ gener
launch gilead older regimen gener impact
less anticip gilead descovi see
hcv gilead saw sequenti declin sale
howev rapid declin begin annual
fourth quarter new author gener version
gilead top hcv drug harvoni epclusa launch
januari could help stabil revenu next year
product launch list price similar net price
brand version lower list price
help gilead penetr medicar part lower out-
of-pocket cost patient state-manag medicaid
see net price brand
version privat cover patient plan also
dovetail trump administr effort lower out-of-
pocket cost often base list price gilead
also look subscript model anoth innov
price strategi state might pay gilead fix
amount treat unlimit number hcv patient
given time expect stabil gilead hcv
franchis perhap slight step-down gilead
compet formulari statu mavyret see
express script decis exclud mavyret
million yescarta sale show slower growth
prior quarter gilead work increas adopt
treatment center begin launch
europ yescarta approv august
addit reimburs improv octob
new add-on payment hospit although reimburs
still complic hospital-
administ therapi treatment typic given
in-pati basi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
